Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.

@article{Jakubowski2007DosedependentIO,
  title={Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.},
  author={Joseph A. Jakubowski and Christopher D. Payne and Govinda Weerakkody and John Brandt and Nagy A. Farid and Ying Li and Hideo Naganuma and D. Richard Lachno and Kenneth J. Winters},
  journal={Journal of cardiovascular pharmacology},
  year={2007},
  volume={49 3},
  pages={167-73}
}
The aims of this open-label, randomized, dose-escalation pharmacodynamic study of prasugrel, an orally active antiplatelet agent, were to assess its interaction with aspirin (ASA, 325 mg) in healthy subjects after a loading dose (LD) and subsequent 5 days of once-daily maintenance doses (MD) of prasugrel or the active comparator, clopidogrel. We measured platelet aggregation induced by ADP, collagen, and TRAP and compared effects on maximal and residual platelet aggregation responses. On a… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.

American journal of cardiovascular drugs : drugs, devices, and other interventions • 2017
View 2 Excerpts

Similar Papers

Loading similar papers…